Company intelligence / Profile preview

NeuroBioPharm

Ownership: Private
Development stage: Other

Overview

NeuroBioPharm was developing marine-based omega‑3 phospholipid therapies for neurological conditions. The company was acquired by Neptune Technologies & Bioressources in early 2015 while still in the early stages of product development with no reported clinical results or approved products. Focus areas included ADHD, cognitive impairment, mood disorders, and general neurodevelopmental/neurodegenerative diseases. No recent updates post-acquisition; ceased to be an independent reporting issuer after February 2015. No evidence of active pipeline since acquisition.

Therapeutic areas: PsychiatryNeurology
Modalities: Omega‑3 phospholipid therapyMedical foodSmall molecule
Industry: Biotech

Beyond the preview

Go deeper on NeuroBioPharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroBioPharm.

Explore the full profile